Organization (Industry)
BOSTON SCIENTIFIC CORPORATION
ClinicalTrials.gov lists BOSTON SCIENTIFIC CORPORATION as lead sponsor of 602 trials, counting the companies grouped under it. BOSTON SCIENTIFIC CORPORATION itself has 28 active development programs and 16 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 38 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 37 in 2026 and about 38 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 38 already registered with a 2026 start date: at the cutoff, 10 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts. 3 trials are registered to start in 2027 or later.
Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers BOSTON SCIENTIFIC CORPORATION and 11 companies grouped under it: 602 lead-sponsored trials (535 its own, 67 in the grouped companies) and 14 legal-entity registrations (8 its own, 6 in the grouped companies).
Companies grouped under this page (11)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Acotec Scientific Co., Ltd | 17 | 0 |
| BTG International (United Kingdom) | 12 | 1 |
| Silk Road Medical (United States) | 10 | 1 |
| Apollo Endosurgery (United States) | 8 | 1 |
| Relievant Medsystems, Inc. | 7 | 0 |
Showing 5 of 11 member companies.
Disease areas (234)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Atrial Fibrillation | 100 |
| Coronary Disease | 90 |
| Coronary Artery Disease | 82 |
| Heart Failure | 76 |
| Pain | 68 |
Showing 5 of 234 disease areas.
Trials by start year as sponsor or collaborator (28)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 38 |
| 2025 | 39 |
| 2024 | 33 |
| 2023 | 25 |
| 2022 | 29 |
| 2021 | 39 |
| 2020 | 35 |
| 2019 | 41 |
| 2018 | 42 |
| 2017 | 32 |
Showing 10 of 28 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 22 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 444 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (28)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| TheraSphere | Liver Neoplasms | Phase 3 | 5 |
| TheraSphere | Carcinoma, Hepatocellular | Phase 3 | 4 |
| (nab)-paclitaxel | Plaque, Amyloid | Phase 3 | 1 |
| (nab)-paclitaxel | Atherosclerosis | Phase 3 | 1 |
| (nab)-paclitaxel | Plaque, Atherosclerotic | Phase 3 | 1 |
Showing 5 of 28 active programs.
Approved assets (16)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Aspirin | 6 |
| Lauromacrogol | 3 |
| Recombinant Tissue Plasminogen Activator | 2 |
| P2Y12 antagonist | 1 |
| Procedure (Tumesent anesthesia) | 1 |
Showing 5 of 16 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 51% hit target (n=190) | 34% on time (n=183) |
Journals published in (348)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of the American College of Cardiology | 92 |
| Circulation | 89 |
| The New England journal of medicine | 49 |
| Circulation. Cardiovascular interventions | 47 |
| JACC. Cardiovascular interventions | 46 |
Showing 5 of 348 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 535 | 39 | 2025-09-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 20,074,000,000 | not reported | 2,052,000,000 |
| 2024 | 16,747,000,000 | not reported | 1,615,000,000 |
| 2023 | 14,240,000,000 | not reported | 1,414,000,000 |
| 2022 | 12,682,000,000 | not reported | 1,323,000,000 |
| 2021 | 11,888,000,000 | not reported | 1,204,000,000 |
| 2020 | 9,913,000,000 | not reported | 1,143,000,000 |
| 2019 | 10,735,000,000 | not reported | 1,174,000,000 |
| 2018 | 9,823,000,000 | not reported | 1,113,000,000 |
| 2017 | 9,048,000,000 | not reported | 997,000,000 |
| 2016 | 8,386,000,000 | not reported | 920,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (56)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-18 | Other financing | not disclosed | Sec extracted |
| 2026-05-15 | Private placement | 1,500,000,000 | Sec extracted |
| 2026-04-01 | Other financing | not disclosed | Edgar offerings |
| 2026-02-26 | Debt financing | not disclosed | Sec extracted |
| 2026-02-26 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 56 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 90 |
FDA recalls (651)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Rapid Refill Continuous Injection System, UPN M00566001 | Class II | 2026-06-30 |
| Radial Jaw 4 Standard Capacity Biopsy Forceps with the following descriptions and UPN: 1. Radial Jaw 4 SC 240cm Box 20; Outer Box UPN: M00513401; Inner Box UPN: M00513400. 2. Radial Jaw 4 SC 240cm Box 40; Outer Box UPN: M00513402; Inner Box UPN: M00513400. 3. Radial Jaw 4 SC w/ Needle 240cm Box 20; Outer Box UPN: M00513411; Inner Box UPN: M00513410. | Class II | 2026-06-30 |
| Radial Jaw 4 Large Capacity Biopsy Forceps with the following descriptions and UPN: 1. Radial Jaw 4 LC 240cm Box 20; Outer Box UPN: M00513321; Inner Box UPN: M00513320. 2. Radial Jaw 4 LC 240cm Box 40; Outer Box UPN: M00513322; Inner Box UPN: M00513320. 3. Radial Jaw 4 LC w/Needle 240cm Box 20; Outer Box UPN: M00513331; Inner Box UPN: M00513330. 4. Radial Jaw 4 LC w/Needle 240cm Box 40; Outer Box UPN: M00513332; Inner Box UPN: M00513330. 5. Radial Jaw 4 LC w/Needle 240cm Box 5; Outer Box UPN: M00513333; Inner Box UPN: M00513330. | Class II | 2026-06-30 |
| Radial Jaw 4 Jumbo Biopsy Forceps with the following descriptions and UPN: Radial Jaw 4 Jumbo 240cm Box 5; Outer Box UPN: M00513363; Inner Box UPN: M00513360. | Class II | 2026-06-30 |
| Boston Scientific TheraSphere 360 Y-90 Management Platform, Model Number M00139509001; Radiological Image Processing System. | Class II | 2026-06-19 |
Showing 5 of 651 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 15 | 2025-09-24 |
Manufacturing and distribution sites (9)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPORATION | Marlborough, US | FDA | |
| Boston Scientific Corporation | Saint Paul, US | FDA | |
| BOSTON SCIENTIFIC CORPORATION | Maple Grove, US | FDA | |
| Boston Scientific Corporation | Roswell, US | FDA | |
| Boston Scientific Corporation | Dorado, US | FDA |
Showing 5 of 9 sites.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (75)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Biocompatibles UK Ltd | Co sponsors trial with | 6 |
| Barts & The London NHS Trust | Co sponsors trial with | 4 |
| Icon Plc | Uses vendor | 3 |
| Oregon Health & Science University | Co sponsors trial with | 3 |
| Iqvia Holdings Inc. | Uses vendor | 3 |
Showing 5 of 75 relationships.
Latest dated events (2,201)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 2,201 events.
CLIA clinical laboratory certificates (5)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| BOSTON SCIENTIFIC | Certificate of waiver | Active |
| BOSTON SCIENTIFIC | Certificate of waiver | Active |
| BOSTON SCIENTIFIC CORP | Certificate of waiver | Terminated |
| BOSTON SCIENTIFIC CORP | Certificate of waiver | Terminated |
| BOSTON SCIENTIFIC CORP | Certificate of waiver | Terminated |
Biomarker capability evidence (812)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial collaborator | Named in trial inclusion criteria |
| AFF1 | Trial collaborator | Named in trial inclusion criteria |
| AFP | Trial collaborator | Named in trial inclusion criteria |
| AGT | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 812 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda untitled letters, and biomarkers this organization publishes on.